The most common non-actionable genomic alterations were found in TP53 (86% of SCLC cases), RB1 (54%) and MLL2 (17%), with NF1 mutations identified in only 3% of SCLC, consistent with the earlier studies. This evidence concerns the gene TP53 and small cell lung carcinoma.